Navigation Links
FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
Date:5/13/2008

DELAND, Fla., May 13 /PRNewswire/ -- USHIFU, LLC, the clinical trial management provider for Focus Surgery, Inc. (Indianapolis, IN), is pleased to announce conditional written approval pending minor changes to the protocol from the FDA to begin a pivotal trial for the treatment of recurrent prostate cancer with the Sonablate(R) 500 in men who have failed external beam radiation therapy.

Dr. Herbert Lepor, Chairman of Urology at NYU School of Medicine and medical monitor for the trial said, "It is my pleasure to serve as the medical monitor for the prostate cancer clinical trial program evaluating the safety and effectiveness of the Sonablate(R) 500 HIFU device."

"I have personally reviewed the preliminary data and observed the Sonablate(R) 500 in action and I am impressed with this advanced technology for ablating the prostate. These rigorous clinical trials will help define the appropriate role of the Sonablate(R) 500 device in the treatment of prostate cancer," Lepor added.

This trial will be conducted at various sites across the U.S. and is expected to enroll approximately 202 subjects and 10 clinical centers. This clinical trial is based on results from the feasibility trial completed in October 2007 which enrolled 11 subjects from two clinical research sites within the U.S. Ten of the eleven subjects had failed external beam radiation therapy prior to participating in the clinical trial. The results of this feasibility trial provided a basis for the pivotal study. Additional studies are still needed to satisfy the safety and effectiveness standards, including long term outcomes, set by the FDA for marketing approval.

The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R) 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate(R) 500 for the treatment of prostate canc
'/>"/>

SOURCE USHIFU, LLC
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
3. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
4. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
7. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
8. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
9. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
10. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
11. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...all/ -- Recession in domestic and international ma...care Products in the first quarter of fiscal year ...es pushed Allied into a loss for the quarter. The...egative 9 cents per share, compared to a net profi...er share. ,, Sales fell about 21 percent in th...
(Date:11/6/2009)...e-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®)...developing and marketing Levulan(®) Photodyna...tients with common skin conditions, announced that... will present a corporate overview at the Merriman...mber 10, 2009 at 10:00 a.m. ET at the Hotel Sofite...
(Date:11/6/2009)...-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:...y, announced today that Paul Bisaro, Watson,s pres... overview and update of the Company,s business at ...e on Wednesday, November 11, 2009 at 12:00 pm East... webcast live and can be accessed on Watson Pharma...
Breaking Medicine Technology:Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6Martek Announces Second Quarter 2009 Financial Results 47844 1Martek Announces Second Quarter 2009 Financial Results 47844 2Martek Announces Second Quarter 2009 Financial Results 47844 3Martek Announces Second Quarter 2009 Financial Results 47844 4Martek Announces Second Quarter 2009 Financial Results 47844 5Martek Announces Second Quarter 2009 Financial Results 47844 6Martek Announces Second Quarter 2009 Financial Results 47844 7Martek Announces Second Quarter 2009 Financial Results 47844 8Martek Announces Second Quarter 2009 Financial Results 47844 9Martek Announces Second Quarter 2009 Financial Results 47844 10Martek Announces Second Quarter 2009 Financial Results 47844 11Martek Announces Second Quarter 2009 Financial Results 47844 12Speaker Pelosi Call Your Science Advisor 21 12454 1Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis 47837 1Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis 47837 2Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis 47837 3
... announced,today that it is planning a European La...io-Thoracic Surgeons (EACTS) meeting in Geneva,Swi...w.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO ...27/CLTU043LOGO ) A summary of the European Clini...Left Ventricular Assist System (LVAS) will be pres...
...ic Natural Physical Environment, MIAMI, Sept. 5 ...ntation as the treatment of choice for type 1 diab...nts often need a re-infusion of islet,cells after ...r pancreas is,needed to provide the fragile islet ...at the Diabetes Research Institute,( http://www.di...
Other Medicine Technology:Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September 2Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells 2
(Date:11/9/2009)...swire/ -- HUYA Bioscience International, a leade...ion, today announced a strategic partnership with ...ity of China. The agreement is another in a series...China,s leading research and development instituti...t and commercialization of novel biopharmaceutical...
(Date:11/9/2009)...y involving 2,453 women ages 18 to 68 found that l...a partner contributed to higher ratings of pleasur...have long been recommended to women to improve the...isk of vaginal tearing, yet strikingly little avai...ts or associated vaginal symptoms. , The study,...
(Date:11/8/2009)...Newswire-USNewswire/ -- The American Public Health...llness provisions in the health reform bill passed...his bill, the House takes important steps toward u...reforms and moving our health system from one that...on keeping people healthy," said Georges C. Benjam...
(Date:11/8/2009)... out of the game later, doctors say , , ...re the talk of the NFL this season, sidelining suc...k Willie Parker. , Officials at the American Po...f Podiatric Sports Medicine are warning athletes t...ts like football and lacrosse. , "Many fall spo...
(Date:11/8/2009)...book called "Preventing and Healing AIDS Thro...o shows that AIDS is a result of multiple, repeate...mmune system stressor agents, which can be either ...motional. , Oakland, CA ... 2009, cell biologists, physicians, chemists and o...
Breaking Medicine News(10 mins):Health News:HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 3Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2Health News:Rx for Fall Foot Injuries 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3
...0 Jobs, HARRISBURG, Pa., Dec. 28 /PRNewswire-USNe...e Williamsport Hospital and Medical Center campus,... a $12.5 million grant,from the commonwealth, the ...ears -- for debt service to the Lycoming County In...
...,Acquisition Corp. ("Echo" or the "Company") (OTC ...unced at its special meeting of stockholders today... provide stockholders,additional time to consider ...us previously mailed to Echo stockholders.,The Ech...
...ission,to provide service, support and hope to all... America (LFA) submitted comments today to Commiss...stration (SSA), regarding a,proposed change to the...be submitted 5 days,before an administrative heari...
...helped for at least a decade , , FRIDAY, D...ly and safely corrects severe myopia for at least ...pia, which is caused by excessive curving of the e...from some degree of nearsightedness. , Laser surge...
...Year,s as the,"world championship" of weight loss,...nd promises. For millions of well-intentioned diet... and, ultimately,disappointment., (See video fro...mber,by Harris Interactive(R) on behalf of GlaxoSm...
... A review published in Dermatologic Therapy revea... procedures in the same way as women but require h...here has recently become a growing interest in cos... often require more units of Botox than women whic...
Other Medicine News:Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4, 2008 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4, 2008 3Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4, 2008 4Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4, 2008 5Health News:Lupus Foundation of America Urges Social Security Administration Not to Adopt Proposed 5-Day Rule 2Health News:Laser Surgery Can Correct Nearsightedness 2Health News:VIDEO from Medialink and GlaxoSmithKline: Really Think You Can 'Lose 30 Pounds in 30 Days?' 2
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
Medicine Products: